ELEDON PHARMACEUTICALS INC (ELDN)
US28617K1016 - Common Stock
Taking everything into account, ELDN scores 3 out of 10 in our fundamental rating. ELDN was compared to 565 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ELDN as it has an excellent financial health rating, but there are worries on the profitability. ELDN has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year ELDN has reported negative net income.
In the past year ELDN has reported a negative cash flow from operations.
In the past 5 years ELDN always reported negative net income.
In the past 5 years ELDN always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -24.18%, ELDN is in the better half of the industry, outperforming 73.31% of the companies in the same industry.
ELDN's Return On Equity of -36.43% is fine compared to the rest of the industry. ELDN outperforms 74.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.18% | ||
| ROE | -36.43% | ||
| ROIC | N/A |
ROA(3y)-53.44%
ROA(5y)-63.75%
ROE(3y)-57.95%
ROE(5y)-70.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ELDN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ELDN has been increased compared to 1 year ago.
ELDN has more shares outstanding than it did 5 years ago.
ELDN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
ELDN has an Altman-Z score of -0.94. This is a bad value and indicates that ELDN is not financially healthy and even has some risk of bankruptcy.
ELDN has a Altman-Z score (-0.94) which is comparable to the rest of the industry.
There is no outstanding debt for ELDN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.94 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ELDN has a Current Ratio of 6.53. This indicates that ELDN is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 6.53, ELDN is doing good in the industry, outperforming 65.12% of the companies in the same industry.
A Quick Ratio of 6.53 indicates that ELDN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.53, ELDN is in the better half of the industry, outperforming 65.30% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.53 | ||
| Quick Ratio | 6.53 |
3. Growth
3.1 Past
ELDN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.22%, which is quite good.
EPS 1Y (TTM)8.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to grow by 7.76% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y34.47%
EPS Next 2Y19.17%
EPS Next 3Y15.3%
EPS Next 5Y7.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ELDN. In the last year negative earnings were reported.
Also next year ELDN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as ELDN's earnings are expected to grow with 15.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.17%
EPS Next 3Y15.3%
5. Dividend
5.1 Amount
ELDN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ELEDON PHARMACEUTICALS INC
NASDAQ:ELDN (12/26/2024, 8:08:55 PM)
After market: 4.23 -0.14 (-3.2%)4.37
+0.1 (+2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners46.06%
Inst Owner Change1.17%
Ins Owners0.05%
Ins Owner Change0%
Market Cap261.06M
Analysts85
Price Target12.75 (191.76%)
Short Float %1.22%
Short Ratio1.19
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-121.06%
Min EPS beat(2)-242.52%
Max EPS beat(2)0.4%
EPS beat(4)3
Avg EPS beat(4)-51.46%
Min EPS beat(4)-242.52%
Max EPS beat(4)27.47%
EPS beat(8)6
Avg EPS beat(8)-23.13%
EPS beat(12)9
Avg EPS beat(12)-13.15%
EPS beat(16)10
Avg EPS beat(16)-16.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.13%
EPS NY rev (1m)26.16%
EPS NY rev (3m)31.75%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.43 | ||
| P/tB | 5.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.01
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-0.63
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0
BVpS1.27
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.18% | ||
| ROE | -36.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-53.44%
ROA(5y)-63.75%
ROE(3y)-57.95%
ROE(5y)-70.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.53 | ||
| Quick Ratio | 6.53 | ||
| Altman-Z | -0.94 |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.57%
EPS Next Y34.47%
EPS Next 2Y19.17%
EPS Next 3Y15.3%
EPS Next 5Y7.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-57.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.95%
OCF growth 3YN/A
OCF growth 5YN/A